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Gilbey et al. report on the results of a double-blind placebo-
controlled trial carried out to investigate the benefits of the
Streptococcus salivarius K12 probiotic usage while undergo-
ing antibiotic treatment for acute pharyngotonsillitis. The re-
sults of their study showed no significant difference between
either treatment group (probiotic or placebo) when used in
conjunction with intravenous penicillin, for any of the param-
eters assessed during the acute phase of the disease. This result
is not surprising considering that the probiotic used is already
well known to be sensitive to penicillin [1–3], and, therefore,
is likely to be killed before it is able to exert its protective
effect. Since the efficacy of penicillin for the treatment of
acute group A Streptococcus (GAS) pharyngitis is well de-
scribed, it would be difficult to envision a scenario where
the S. salivarius probiotic could enhance the clearance rate
of GAS and reduce the time required for recovery.
In their justification for carrying out this investigation, the
authors cite examples of probiotics that have reduced the du-
ration of acute respiratory tract infections in support of their
trial design [4]. However, these were carried out without the
complication of co-treatment with antibiotics; therefore, it is
not clear whether the benefits would still have been observed
if antibiotics were a component of the treatment regimes [4].
Another example cited by the authors demonstrated a benefit
from the concomitant administration of antibiotics, and an
antibiotic-resistant probiotic for reducing the recurrence rates of
urinary tract infections in children [5]. Again, this is a different
trial design when compared to that carried out byGilbey et al., as
it is not investigating the effect on acute symptoms of the disease.
A more informative trial assessing the benefits of K12 dur-
ing acute infection would be to investigate the downstream
effect of K12 when used in conjunction with penicillin, and
continued post-antibiotic therapy, for the prevention of sec-
ondary infections or recurrences of GAS. Previous studies have
clearly demonstrated that daily consumption of S. salivariusK12
can reduce GAS pharyngotonsillitis recurrence rates by up to
90 % [6–8], and this would surely be worth investigating as a
potential positive outcome from a co-treatment regime, before
recommending that K12 should not be combinedwith antibiotics.
Therefore, with the considerations above, the recommen-
dation of the study’s authors not to combine S. salivariusK12
with antibiotic treatment for acute pharyngitis cases seems
premature. While an immediate benefit related to pain scores
and immune marker levels may not have been observed, com-
bined treatment, particularly as an adjunct therapy that extends
beyond the period of antibiotic dosing, is likely to still yield
significant benefits for the patient when the downstream ef-
fects are considered, compared to antibiotic treatment alone.
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